PLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
PLIANT THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$0.90−0.00 (-0.13%)
Close on Oct 19, 2026
- Market cap
- $55.65M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Margins
Share of revenue, fiscal years 2018 to 2025
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -40.2% | -61.5% | |
| Return on assets | – | -20.0% | -48.0% | |
| Current ratio | – | 25.07 | 12.00 | |
| Interest coverage | – | – | -61.1× | |
| Capex to revenue | – | 3.7% | – | |
| Diluted shares | – | 21M | 61M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Pliant Therapeutics generated $570.27M from operations and spent $8.86M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$570.27M
Used
$8.86M
Capital expenditure$8.86M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-10211.1%
×Asset turnover0.00×
×Equity multiplier1.10×
=Return on equity, FY2023-41.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2023 | -10211.1% | 0.00× | 1.10× | -41.0% |
| FY2022 | -1273.3% | 0.03× | 1.12× | -48.1% |
| FY2021 | -1284.5% | 0.03× | 1.07× | -40.3% |
| FY2020 | -99.3% | 0.20× | 2.01× | -40.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$149.34M
- Cash generatingOperating cash flow above zero-$128.34M
- Return on assets improvedROA up on the prior year-41.1% → -37.6%
- Earnings backed by cashOperating cash flow above net income-$128.34M vs -$149.34M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose10.91 → 12.00
- No dilutionShare count did not rise61M → 61M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.00 → 0.00